Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoglitazone in Type 2 Diabetes Mellitus
NCT01103414Phase 2Completed
- Sponsor
- Metabolic Solutions Development Company
- Start
- Sep 2010
- Primary completion
- Nov 2011
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Mitoglitazone in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Metabolic Solutions Development Company. Primary endpoint: Fasting Plasma Glucose at 12 weeks. Started Sep 2010; status: completed.
02
Drugs
Mitoglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01103414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103414.